NCT05611931
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatmentKaryopharm Therapeutics Inc
~257 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:SelinexorMatching Placebo for selinexor
At a glance
Recruiting sites
0 of 199 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Investigator assessed Progression Free Survival (PFS) per RECIST v1.1
Measured over From randomization until disease progression (PD) or death, whichever occurs first (up to 34 months)
Conditions
Where it's being run
199 sites across 57 statesSpain19
Italy15
Georgia11
Germany11
California8
Texas8
New York7
New South Wales7
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Adults (Aged ≥ 18 years)
Histologically confirmed endometrial cancer (endometrioid, serous, undifferentiated, or carcinosarcoma sub-types) that is TP53 wild type by central NGS
Must have completed at least 12 weeks of platinum-based chemotherapy (with or without immune checkpoint inhibitors), with a confirmed partial or complete response according to RECIST v1.1
Must be able to initiate C1D1 within 3-8 weeks after last platinum dose
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate bone marrow function and organ function
Exclusion
Uterine sarcomas, clear cell or small cell carcinoma with neuroendocrine differentiation
Palliative radiotherapy administered within 14 days of intended C1D1
Any gastrointestinal dysfunction that could interfere with the absorption of oral study therapy
Serious psychiatric or medical conditions that could interfere with study participation or would make study involvement unreasonably hazardous
Previous treatment with an XPO1 inhibitor
Stable disease or disease progression after platinum-based chemotherapy
Pregnancy, breastfeeding, or other legal/ethical restrictions to trial participation
Known dMMR/MSI-H EC tumors that are medically eligible to receive an immune checkpoint inhibitor
What this trial measures
- Investigator assessed Progression Free Survival (PFS) per RECIST v1.1From randomization until disease progression (PD) or death, whichever occurs first (up to 34 months)